Increasing evidence illustrates the value of plasma biomarkers of Alzheimer’s disease (AD) to screen for and identify dementia with Lewy bodies (DLB). However, confirmatory studies are needed to demonstrate the feasibility of these markers.
Objective:
To determine the feasibility of plasma tau phosphorylated at threonine 181 (p-tau181) and amyloid-β42 (Aβ42) as potential biomarkers to differentiate AD and DLB.
Methods:
We evaluated plasma samples from patients with DLB (n = 47) and AD (n = 55) and healthy controls (HCs, n = 30), using ELISAs to measure p-tau181 and Aβ42. Additionally, we examined neuropsychological assessment scores for participants. The plasma biomarkers were investigated for correlation with neuropsychological assessments and discriminant ability to identify DLB.
Results:
Plasma p-tau181 was significantly lower in DLB than in AD and HCs. Plasma Aβ42 was significantly higher in DLB than in AD but lower in DLB than in HCs. We found good correlations between plasma Aβ42 and neuropsychological scores in the whole cohort, while p-tau181 was associated with cognitive status in DLB. In the distinction between DLB and HCs, plasma p-tau181 and Aβ42 showed similar accuracy, while Aβ42 showed better accuracy than p-tau181 in discriminating DLB and AD.
Conclusion:
In a single-center clinical cohort, we confirmed the high diagnostic value of plasma p-tau181 and Aβ42 for distinguishing patients with DLB from HCs. Plasma Aβ42 improved the differential diagnosis of DLB from AD.
OuteiroTF, KossDJ, ErskineD, WalkerL, Kurzawa-AkanbiM, BurnD, DonaghyP, MorrisC, TaylorJP, ThomasA, AttemsJ, McKeithI (2019) Dementia with Lewy bodies: An update and outlook. Mol Neurodegener14, 5.
2.
WalkerZ, PossinKL, BoeveBF, AarslandD (2015) Lewy body dementias. Lancet386, 1683–1697.
3.
Vann JonesSA, O’BrienJT (2014) The prevalence and incidence of dementia with Lewy bodies: A systematic review of population and clinical studies. Psychol Med44, 673–683.
AshtonNJ, HyeA, RajkumarAP, LeuzyA, SnowdenS, Suarez-CalvetM, KarikariTK, SchollM, La JoieR, RabinoviciGD, HoglundK, BallardC, HortobagyiT, SvenningssonP, BlennowK, ZetterbergH, AarslandD (2020) An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. Nat Rev Neurol16, 265–284.
6.
IrwinDJ, GrossmanM, WeintraubD, HurtigHI, DudaJE, XieSX, LeeEB, Van DeerlinVM, LopezOL, KoflerJK, NelsonPT, JichaGA, WoltjerR, QuinnJF, KayeJ, LeverenzJB, TsuangD, LongfellowK, YearoutD, KukullW, KeeneCD, MontineTJ, ZabetianCP, TrojanowskiJQ (2017) Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: A retrospective analysis. Lancet Neurol16, 55–65.
7.
JanelidzeS, MattssonN, PalmqvistS, SmithR, BeachTG, SerranoGE, ChaiX, ProctorNK, EichenlaubU, ZetterbergH, BlennowK, ReimanEM, StomrudE, DageJL, HanssonO (2020) Plasma P-tau181 in Alzheimer’s disease: Relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia. Nat Med26, 379–386.
8.
PalmqvistS, TidemanP, CullenN, ZetterbergH, BlennowK, Alzheimer’s Disease NeuroimagingI, DageJL, StomrudE, JanelidzeS, Mattsson-CarlgrenN, HanssonO (2021) Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures. Nat Med27, 1034–1042.
9.
PalmqvistS, JanelidzeS, StomrudE, ZetterbergH, KarlJ, ZinkK, BittnerT, MattssonN, EichenlaubU, BlennowK, HanssonO (2019) Performance of fully automated plasma assays as screening tests for Alzheimer disease-related beta-amyloid status. JAMA Neurol76, 1060–1069.
10.
McKhannG, DrachmanD, FolsteinM, KatzmanR, PriceD, StadlanEM (1984) Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology34, 939–944.
ChinKS, YassiN, ChurilovL, MastersCL, WatsonR (2020) Prevalence and clinical associations of tau in Lewy body dementias: A systematic review and meta-analysis. Parkinsonism Relat Disord80, 184–193.
13.
DonaghyPC, FirbankMJ, ThomasAJ, LloydJ, PetridesG, BarnettN, OlsenK, O’BrienJT (2020) Amyloid imaging and longitudinal clinical progression in dementia with Lewy bodies. Am J Geriatr Psychiatry28, 573–577.
FerreiraD, PrzybelskiSA, LesnickTG, LemstraAW, LondosE, BlancF, NedelskaZ, SchwarzCG, Graff-RadfordJ, SenjemML, FieldsJA, KnopmanDS, SavicaR, FermanTJ, Graff-RadfordNR, LoweVJ, JackCR Jr, PetersenRC, MollenhauerB, Garcia-PtacekS, AbdelnourC, HortJ, BonanniL, OppedalK, KrambergerMG, BoeveBF, AarslandD, WestmanE, KantarciK (2020) beta-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies. Neurology95, e3257–e3268.
16.
van SteenovenI, van der FlierWM, ScheltensP, TeunissenCE, LemstraAW (2019) Amyloid-beta peptides in cerebrospinal fluid of patients with dementia with Lewy bodies. Alzheimers Res Ther11, 83.
17.
BousigesO, PhilippiN, LavauxT, Perret-LiaudetA, LachmannI, Schaeffer-AgaledeC, AnthonyP, BotzungA, RauchL, JungB, de SousaPL, DemuynckC, Martin-HunyadiC, CretinB, BlancF (2020) Differential diagnostic value of total alpha-synuclein assay in the cerebrospinal fluid between Alzheimer’s disease and dementia with Lewy bodies from the prodromal stage. Alzheimers Res Ther12, 120.
18.
ChiasseriniD, BiscettiL, EusebiP, SalvadoriN, FrattiniG, SimoniS, De RoeckN, TambascoN, StoopsE, VandersticheleH, EngelborghsS, MollenhauerB, CalabresiP, ParnettiL (2017) Differential role of CSF fatty acid binding protein 3, alpha-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia. Alzheimers Res Ther9, 52.
19.
JanelidzeS, StomrudE, PalmqvistS, ZetterbergH, van WestenD, JerominA, SongL, HanlonD, Tan HehirCA, BakerD, BlennowK, HanssonO (2016) Plasma beta-amyloid in Alzheimer’s disease and vascular disease. Sci Rep6, 26801.
20.
MehtaPD, PirttilaT, MehtaSP, SersenEA, AisenPS, WisniewskiHM (2000) Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol57, 100–105.
21.
O’BrienJT, FirbankMJ, DavisonC, BarnettN, BamfordC, DonaldsonC, OlsenK, HerholzK, WilliamsD, LloydJ (2014) 18F-FDG PET and perfusion SPECT in the diagnosis of Alzheimer and Lewy body dementias. J Nucl Med55, 1959–1965.
22.
BaiardiS, QuadaltiC, MammanaA, DellavalleS, ZenesiniC, SambatiL, PantieriR, PolischiB, RomanoL, SuffrittiM, BentivengaGM, RandiV, Stanzani-MaseratiM, CapellariS, ParchiP (2022) Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias. Alzheimers Res Ther14, 153.
23.
DonaghyPC, FirbankM, PetridesG, LloydJ, BarnettN, OlsenK, HeslegraveA, ZetterbergH, ThomasAJ, O’BrienJT (2022) The relationship between plasma biomarkers and amyloid PET in dementia with Lewy bodies. Parkinsonism Relat Disord101, 111–116.
24.
HallS, JanelidzeS, LondosE, LeuzyA, StomrudE, DageJL, HanssonO (2021) Plasma phospho-tau identifies Alzheimer’s co-pathology in patients with Lewy body disease. Mov Disord36, 767–771.
25.
GonzalezMC, AshtonNJ, GomesBF, Tovar-RiosDA, BlancF, KarikariTK, MollenhauerB, PilottoA, LemstraA, PaquetC, AbdelnourC, KrambergerMG, BonanniL, VandenbergheR, HyeA, BlennowK, ZetterbergH, AarslandD, European– Dementia With Lewy Bodies (E-DLB) Consortium (2022) Association of plasma p-tau181 and p-tau231 concentrations with cognitive decline in patients with probable dementia with Lewy bodies. JAMA Neurol79, 32–37.
26.
ThomasAJ, HamiltonCA, HeslegraveA, BarkerS, DurcanR, LawleyS, BarnettN, LettD, FirbankM, RobertsG, TaylorJP, DonaghyPC, ZetterbergH, O’BrienJ (2022) A longitudinal study of plasma pTau181 in mild cognitive impairment with Lewy bodies and Alzheimer’s disease. Mov Disord37, 1495–1504.
27.
KarikariTK, BenedetAL, AshtonNJ, Lantero RodriguezJ, SnellmanA, Suarez-CalvetM, Saha-ChaudhuriP, LussierF, KvartsbergH, RialAM, PascoalTA, AndreassonU, SchollM, WeinerMW, Rosa-NetoP, TrojanowskiJQ, ShawLM, BlennowK, ZetterbergH, Alzheimer’s Disease Neuroimaging Initiative (2021) Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative. Mol Psychiatry26, 429–442.
28.
BatzuL, RotaS, HyeA, HeslegraveA, TrivediD, GibsonLL, FarrellC, ZinzaliasP, RizosA, ZetterbergH, ChaudhuriKR, AarslandD (2022) Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson’s disease. NPJ Parkinsons Dis8, 154.
29.
PagonabarragaJ, Perez-GonzalezR, Bejr-KasemH, Marin-LahozJ, Horta-BarbaA, Martinez-HortaS, Aracil-BolanosI, SampedroF, CampolongoA, RivasE, Puig-DaviA, Ruiz-BarriosI, Perez-PerezJ, Pascual-SedanoB, KulisevskyJ (2022) Dissociable contribution of plasma NfL and p-tau181 to cognitive impairment in Parkinson’s disease. Parkinsonism Relat Disord105, 132–138.
30.
ChouliarasL, ThomasA, MalpettiM, DonaghyP, KaneJ, MakE, SavulichG, Prats-SedanoMA, HeslegraveAJ, ZetterbergH, SuL, RoweJB, O’BrienJT (2022) Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer’s disease, frontotemporal dementia and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry93, 651–658.
31.
deOliveira FF, MiraldoMC, de Castro-NetoEF, de AlmeidaSS, MatasSLA, BertolucciPHF, Naffah-MazzacorattiMDG (2021) Associations of neuropsychiatric features with cerebrospinal fluid biomarkers of amyloidogenesis and neurodegeneration in dementia with Lewy bodies compared with alzheimer’s disease and cognitively healthy people. J Alzheimers Dis81, 1295–1309.
